A pivotal trial of VB 111 in patients with platinum resistant ovarian cancer
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Ofranergene obadenovec (Primary)
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- Acronyms OVAL
- Sponsors VBL Therapeutics
- 14 Aug 2017 According to a VBL Therapeutics media release, the company is on track to initiate this trial by the year-end 2017.
- 12 Jan 2017 New trial record
- 09 Jan 2017 According to a VBL Therapeutics media release, this trial is expected to initiate in the second half of 2017.